Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) Non Operating Investment Income (2019 - 2023)

Historic Non Operating Investment Income for Bioadaptives (BDPT) over the last 5 years, with Q4 2023 value amounting to -$11.0.

  • Bioadaptives' Non Operating Investment Income fell 21000.0% to -$11.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$11.0, marking a year-over-year increase of 4761.9%. This contributed to the annual value of -$42.0 for FY2023, which is 7162.16% up from last year.
  • Per Bioadaptives' latest filing, its Non Operating Investment Income stood at -$11.0 for Q4 2023, which was down 21000.0% from -$11.0 recorded in Q3 2023.
  • In the past 5 years, Bioadaptives' Non Operating Investment Income ranged from a high of $5901.0 in Q4 2019 and a low of -$2517.0 during Q2 2021
  • Moreover, its 5-year median value for Non Operating Investment Income was -$26.0 (2022), whereas its average is $122.15.
  • Data for Bioadaptives' Non Operating Investment Income shows a peak YoY increase of 88722.22% (in 2021) and a maximum YoY decrease of 62120.34% (in 2021) over the last 5 years.
  • Over the past 5 years, Bioadaptives' Non Operating Investment Income (Quarter) stood at $5901.0 in 2019, then crashed by 99.1% to $53.0 in 2020, then plummeted by 379.25% to -$148.0 in 2021, then skyrocketed by 106.76% to $10.0 in 2022, then plummeted by 210.0% to -$11.0 in 2023.
  • Its Non Operating Investment Income was -$11.0 in Q4 2023, compared to -$11.0 in Q3 2023 and -$10.0 in Q2 2023.